Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer
- 10 August 2007
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 57 (3) , 337-345
Abstract
Human Vα24 natural killer T (NKT) cells are activated by the specific ligand, α-galactosylceramide (α-GalCer), in a CD1d-dependent manner. Potent anti-tumor activity of activated NKT cells has been previously demonstrated.Keywords
This publication has 33 references indexed in Scilit:
- A Phase I Study ofIn vitroExpanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Emerging drugs for head and neck cancerExpert Opinion on Emerging Drugs, 2006
- Natural killer T cell‐mediated antitumor immune responses and their clinical applicationsCancer Science, 2006
- Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymph nodeJournal of Leukocyte Biology, 2005
- Dendritic cell maturation by CD11c− T cells and Vα24+ natural killer T‐cell activation by α‐GalactosylceramideInternational Journal of Cancer, 2005
- Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsJournal of Experimental Medicine, 2005
- Selective induction of NK cell proliferation and cytotoxicity by activated NKT cellsEuropean Journal of Immunology, 2000
- THE CD1 SYSTEM: Antigen-Presenting Molecules for T Cell Recognition of Lipids and GlycolipidsAnnual Review of Immunology, 1999
- MOUSE CD1-SPECIFIC NK1 T CELLS: Development, Specificity, and FunctionAnnual Review of Immunology, 1997
- Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432The Journal of Laryngology & Otology, 1996